Drug intelligence / Profile preview

aliskiren + amlodipine

Development stage
Unknown
Lead developer
Novartis
Modality
Small Molecules
Administration
Oral
01

Overview

Aliskiren + amlodipine is an oral fixed-dose combination antihypertensive medication used to treat high blood pressure (hypertension). It combines two agents with complementary mechanisms of action. Aliskiren is a direct renin inhibitor that blocks the activity of renin, an enzyme involved in the production of angiotensin I, thereby reducing the formation of angiotensin II and leading to vasodilation and decreased blood pressure. Amlodipine is a dihydropyridine calcium channel blocker that inhibits calcium influx into vascular smooth muscle and cardiac muscle cells, resulting in relaxation of blood vessels and further reduction in blood pressure. The combination has been shown to be more effective than amlodipine alone for lowering blood pressure. It is marketed under brand names such as Tekamlo and Rasilamlo[1][3][5][8].

Brand names
TekamloRasilamlo
Other names
aliskiren/amlodipine
02

Targets

REN (Renin)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)

Beyond the preview

Go deeper on aliskiren + amlodipine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aliskiren + amlodipine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call